Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study
- PMID: 17014595
- DOI: 10.1111/j.1526-4637.2006.00207.x
Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study
Abstract
Objective: Duloxetine is a relatively balanced and potent reuptake inhibitor of both serotonin and norepinephrine. Because these neurotransmitters play a role in pain inhibition, duloxetine was considered a possible treatment for diabetic peripheral neuropathic pain (DPNP). This study assessed the 6-month safety and tolerability of duloxetine in patients with DPNP; evaluation of efficacy was a secondary objective.
Design: In this 28-week, open-label study, in the clinical setting, 449 patients with DPNP were randomized (3:1) to receive duloxetine 60 mg twice daily (BID) (N = 334) or duloxetine 120 mg once daily (QD) (N = 115). Comprehensive safety evaluations including laboratory analyses and electrocardiograms were performed for all patients. Efficacy measures included the Brief Pain Inventory (BPI) and Clinical Global Impression of Severity (CGI-S) scales.
Results: Protocol completion rates were 63.8% and 62.6% for the 60 mg BID and 120 mg QD groups, respectively (P = 0.823). Discontinuations were primarily due to adverse events, 20.1% for 60 mg BID and 27.0% for 120 mg QD (P = 0.149). Heart rate increased slightly in both treatment groups (P </= 0.02 in both groups). Systolic blood pressure was unaffected, while diastolic blood pressure decreased slightly in the 120 mg QD group (P = 0.04). Sustained elevation in blood pressure was reported for 18 (5.5%) patients in the 60 mg BID group and six (5.4%) in the 120 mg QD group. Duloxetine treatment was not associated with significant QTc prolongation. There was significant improvement at endpoint on all subscales of the BPI and CGI-S (P < 0.001 in both groups).
Conclusions: In this study, duloxetine 60 mg BID and 120 mg QD were safely administered and well tolerated in patients with DPNP for up to 28 weeks. There were few differences in safety or tolerability between the two dosages. At both doses, duloxetine provided clinically significant pain relief.
Similar articles
-
A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.Neurology. 2006 Oct 24;67(8):1411-20. doi: 10.1212/01.wnl.0000240225.04000.1a. Neurology. 2006. PMID: 17060567 Clinical Trial.
-
Duloxetine for the management of diabetic peripheral neuropathic pain: response profile.Pain Med. 2007 Jul-Aug;8(5):397-409. doi: 10.1111/j.1526-4637.2007.00305.x. Pain Med. 2007. PMID: 17661853 Clinical Trial.
-
Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes.Pain Med. 2007 Jul-Aug;8(5):410-8. doi: 10.1111/j.1526-4637.2007.00276.x. Pain Med. 2007. PMID: 17661854 Clinical Trial.
-
Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.Am J Health Syst Pharm. 2005 Dec 1;62(23):2481-90. doi: 10.2146/ajhp050006. Am J Health Syst Pharm. 2005. PMID: 16303903 Review.
-
Review of duloxetine in the management of diabetic peripheral neuropathic pain.Vasc Health Risk Manag. 2007;3(6):833-44. Vasc Health Risk Manag. 2007. PMID: 18200804 Free PMC article. Review.
Cited by
-
Spinal cord vascular degeneration impairs duloxetine penetration.Front Pain Res (Lausanne). 2023 May 26;4:1190440. doi: 10.3389/fpain.2023.1190440. eCollection 2023. Front Pain Res (Lausanne). 2023. PMID: 37325676 Free PMC article.
-
Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials.BMC Neurol. 2008 Aug 1;8:29. doi: 10.1186/1471-2377-8-29. BMC Neurol. 2008. PMID: 18673529 Free PMC article.
-
A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial.Diabetes Care. 2011 Apr;34(4):818-22. doi: 10.2337/dc10-1793. Epub 2011 Feb 25. Diabetes Care. 2011. PMID: 21355098 Free PMC article. Clinical Trial.
-
Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52-week, open-label study.J Diabetes Investig. 2016 Jan;7(1):100-8. doi: 10.1111/jdi.12361. Epub 2015 May 18. J Diabetes Investig. 2016. PMID: 26816607 Free PMC article. Clinical Trial.
-
Recent advances in the pharmacological management of pain.Drugs. 2007;67(15):2121-33. doi: 10.2165/00003495-200767150-00002. Drugs. 2007. PMID: 17927280 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical